More information: Insung Park et al, Orexin receptor antagonist increases fat oxidation and suppresses protein catabolism during sleep in humans, iScience (2024). DOI: 10.1016/j.isci.2024.110212 ...

Daridorexant is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating ...

Nxera Pharma inks agreement with Holling Bio-Pharma to commercialize daridorexant in Taiwan: Tokyo, Japan Monday, March 3, 2025, 16:00 Hrs [IST] Nxera Pharma Co., Ltd. announces t ...

Orexin antagonists, meanwhile – such as Eisai's Dayvigo (lemborexant), Merck & Co's Belsomra (suvorexant) and Idorsia's recently filed daridorexant – have proved effective as treatments for ...

Q4 2024 Management View CEO Richard Pops highlighted 2024 as a transformative year focused on profitability and pipeline development, achieving over $1.5 billion in revenue and $450 million in EBITDA ...

NLS Pharmaceutics (NLSP) announces new preclinical findings on AEX-2, reinforcing its potential as a first-in-class non-sulfonamide dual orexin ...

NLS Pharmaceutics Ltd., in collaboration with Aexon Labs Inc., has announced new preclinical findings on AEX-2, a non-sulfonamide dual orexin receptor agonist (DOXA) with potential for narcolepsy and ...

Bial-Portela & Ca SA has identified orexin OX1 receptor antagonists reported to be useful for the treatment of cognitive, sleep, anxiety and eating disorders, depression, obesity, schizophrenia, ...

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

The two major types of narcolepsy are: Narcolepsy type 1. People with type 1 narcolepsy have low levels of orexin (hypocretin), a brain chemical that regulates wakefulness. Damage to the brain ...